bigfoot biomedical
-
Devices & Diagnostics, Health Tech
Abbott-Bigfoot Deal Proves That Diabetes Is a Hot Area for Digital Health Investment
This week, Abbott announced its plans to acquire Bigfoot Biomedical — a startup selling a “smart” insulin pen cap, which collects data from a user’s CGM to help them calculate the right dose. Most analysts were unsurprised to hear of the acquisition given that the two companies have been collaborating for more than six years, but they said the deal reinforces the steady pace of digital innovation in the diabetes care space.
-
Bigfoot Biomedical gets FDA clearance for ‘smart’ insulin pen caps
The startup received 510(k) clearance for its “smart” insulin pen cap, which pulls in data from users’ connected glucose monitor to help them calculate the right dose.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Devices & Diagnostics, Health Tech
With $55M in new funding, Bigfoot Biomedical takes strides toward FDA submission
Bigfoot Biomedical plans to submit an application to the FDA for clearance of its smart insulin pen caps this month. The devices pull in information from a connected glucose monitor to help users calculate the optimal insulin with each meal.
-
Bigfoot Biomedical lands $45M as it readies first diabetes product
The money will help the company launch its first insulin-management product by the end of this year, which is likely to face stiff competition from larger rivals.
-
Rock Health: Digital health investing has already surpassed record-breaking 2017
In 2018 alone, ten companies have inked mega-deals of more than $100 million including Livongo, 23andMe and American Well.
-
Bigfoot brings in $55M Series B to propel integrated diabetes platform
The California startup is attempting to create a closed-loop and integrated diabetes platform that attracted Abbott, whic has been a partner since July to invest.
-
Bigfoot Biomedical closes $37M Series B as it prepares for clinical trials of insulin delivery tech
Bigfoot Biomedical CEO Jeffrey Brewer said in an email that the company expects to begin pivotal trials in the second half of 2018.
-
From Bigfoot Biomedical’s artificial pancreas to the athenahealth accelerator: 5 must-read stories from MedCity News this week
On MedHeads Friday, we covered everything from Dr. Patrick Soon-Shiong’s continued funding for NantBioscience, our […]
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
